Using GE Lunar DXA to Quantify, Visualize, and Trend Incipient Atypical Femoral Fractures
The management of osteoporosis underwent a paradigm shift in 1995 with the approval of the first bisphosphonate, risedronate. Since then, several other bisphosphonates have been approved, including alendronate, ibandronate, and zoledronate, as well as the first biologic treatment for osteoporosis, denosumab. These drugs reduce fracture risk by decreasing bone resorption. Their use is attributed to a significant reduction in the incidence and mortality of hip fractures since 1995.